Horn Kinney sold $2.3M of IMNM
Horn Kinney (CHIEF BUSINESS OFFICER) sold 90,616 shares of Immunome Inc. (IMNM) at $25.09 ($2.27M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Horn Kinney sold shares at a specific price and date; the disclosure does not include any new company performance, guidance, or regulatory/clinical catalyst.
Market read
Traders may note the insider sale for sentiment, but there is no new fundamental information to drive a durable repricing.
What to watch
The filing shows shares sold and post-transaction holdings (0 shares), but it does not reveal whether other insiders or the company simultaneously announced new fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for Immunome Inc.
Ticker impact
Immunome disclosed via Form 4 that Horn Kinney, Chief Business Officer, sold 90,616 shares at $25.09 on Aug 4 under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; no clear directional fundamental signal from the filing alone.
The filing is a routine Form 4 transaction with a stated 10b5-1 pre-arranged plan and no accompanying guidance, deal, or operational change.
Market effects
Minimal; insider selling in a single biotech does not reset sector expectations without additional company-specific catalysts.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity management rather than bearish expectations.
Key entities
- issuerImmunome Inc.
Company subject of the Form 4 insider transaction disclosure.
- insiderHorn Kinney
Chief Business Officer who executed the reported open-market sale under a 10b5-1 plan.